Key Highlights

  • Daré Bioscience shares closed down 32% at $1.34.
  • The company received formal notification from Nasdaq on July 13, 2026 regarding a stockholders' equity deficiency.
  • Daré failed to maintain the $2.5 million minimum required under Nasdaq Listing Rule 5550(b).
  • The company also does not currently meet alternative listing criteria.

Daré Bioscience (NASDAQ: DARE) shares closed down 32% at $1.34 after the company received formal notification from the Nasdaq Listing Qualifications Staff on July 13, 2026, regarding a deficiency in stockholders' equity.

What Happened

The company failed to maintain the $2.5 million minimum stockholders' equity required by Nasdaq Listing Rule 5550(b), as reported in its most recent Form 10-Q.

Daré also does not currently meet alternative listing criteria, which include a $35 million market value of securities or $500,000 in net income from continuing operations.

Market Reaction

Shares fell 32% to close at $1.34 following the Nasdaq notification, reflecting investor concern over the company's listing status.

The scale of the decline suggests the market is treating the deficiency notice as a significant negative development, given the potential implications for the stock's continued Nasdaq listing.

Outlook

The disclosed information does not include detail on any compliance plan Daré may submit to Nasdaq or a specific timeline for resolving the deficiency.

Why did Daré Bioscience shares fall 32%?

Shares fell after the company received a Nasdaq notice citing a deficiency in stockholders' equity.

What Nasdaq rule did Daré fail to meet?

The company failed to maintain the $2.5 million minimum stockholders' equity required by Nasdaq Listing Rule 5550(b).

Does Daré meet any alternative listing criteria?

No, the company does not currently meet alternative criteria, which include a $35 million market value of securities or $500,000 in net income from continuing operations.